Advances in Nanomedicine for Targeted Drug Delivery Systems
DOI:
https://doi.org/10.37899/mjdh.v1i2.68Keywords:
Nanomedicine, Targeted Drug Delivery, NanoparticlesAbstract
Advancements in nanomedicine have revolutionized drug delivery systems, enabling targeted therapies that enhance drug efficacy and reduce systemic toxicity. This review explores recent developments in nanoparticle-based drug delivery systems, focusing on various types of nanoparticles, including liposomes, polymeric nanoparticles, dendrimers, and stimuli-responsive systems. The mechanisms of targeted drug delivery, including passive and active targeting strategies, are discussed, highlighting the role of the enhanced permeability and retention (EPR) effect. Clinical applications, particularly in oncology and neurodegenerative diseases, are examined, showcasing the potential of these systems to improve patient outcomes. Despite the promising advances, challenges such as safety, scalability, and regulatory hurdles remain significant obstacles to the widespread clinical adoption of nanoparticle-based therapies. Future directions emphasize the integration of nanomedicine with emerging technologies and personalized medicine, paving the way for innovative therapeutic solutions.
References
Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36-48.
https://doi.org/10.1016/j.addr.2012.09.037
Bae, Y. H., & Park, K. (2011). Targeted drug delivery to tumors: Myths, reality and possibility. Journal of Controlled Release, 153(3), 198-205.
https://doi.org/10.1016/j.jconrel.2011.06.001
Barenholz, Y. (2012). Doxil®—the first FDA-approved nano-drug: Lessons learned. Journal of Controlled Release, 160(2), 117-134.
https://doi.org/10.1016/j.jconrel.2012.03.020
Chauhan, A. S. (2013). Dendrimers for drug delivery. Molecules, 18(7), 8441-8463.
https://doi.org/10.3390/molecules18078441
Cheng, Y., Dai, Q., & Morshed, R. A. (2014). Nano-prodrugs: an emerging paradigm for cancer therapy. Nature Reviews Drug Discovery, 13(1), 87-106.
https://doi.org/10.1038/nrd4176
Danhier, F., Feron, O., & Préat, V. (2010). To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release, 148(2), 135-146.
https://doi.org/10.1016/j.jconrel.2010.08.027
Gabizon, A., & Shmeeda, H. (2021). PEGylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy. Expert Opinion on Drug Delivery, 18(7), 929-940.
https://doi.org/10.1080/17425247.2021.1922061
Gu, F., Zhang, L., & Teply, B. A. (2008). Targeted nanoparticles for cancer therapy. Nano Today, 2(3), 14-21.
https://doi.org/10.1016/S1748-0132(08)70058-2
Karimi, M., Ghasemi, A., Zangabad, P. S., Rahighi, R., Basri, S. M. M., Mirshekari, H., ... & Hamblin, M. R. (2016). Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chemical Society Reviews, 45(5), 1457-1501.
https://doi.org/10.1039/C5CS00798D
Kesharwani, P., Jain, K., & Jain, N. K. (2014). Dendrimer as nanocarrier for drug delivery. Progress in Polymer Science, 39(2), 268-307.
https://doi.org/10.1016/j.progpolymsci.2013.07.005
Kwon, G. S., & Okano, T. (1999). Polymeric micelles for drug delivery. Journal of Controlled Release, 57(2), 191-202.
https://doi.org/10.1016/S0168-3659(98)00280-0
Li, Y., Deng, G., Hu, X., Li, C., Wang, X., Zhu, Q., ... & Wu, H. (2022). Recent advances in mesoporous silica nanoparticle-based targeted drug-delivery systems for cancer therapy. Nanomedicine, 17(18), 1253-1279.
https://doi.org/10.2217/nnm-2022-0023
Maeda, H., Wu, J., & Sawa, T. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. Journal of Controlled Release, 65(1-2), 271-284.
https://doi.org/10.1016/S0168-3659(99)00248-5
Mura, S., Nicolas, J., & Couvreur, P. (2013). Stimuli-responsive nanocarriers for drug delivery. Nature Materials, 12(11), 991-1003.
https://doi.org/10.1038/nmat3776
Rahman, M. M., & Cheong, W. C. (2014). Synthesis and characterization of pH-sensitive nanoparticles for drug delivery. Materials Science and Engineering: C, 41, 50-56.
https://doi.org/10.1016/j.msec.2014.04.019
Sahoo, S. K., & Panyam, J. (2007). Nanoparticles as drug delivery systems. Nanomedicine: Nanotechnology, Biology, and Medicine, 3(3), 202-210.
https://doi.org/10.1016/j.nano.2007.04.002
Srivastava, N., Chudasama, B., & Baranwal, M. (2023). Advancement in magnetic hyperthermia-based targeted therapy for cancer treatment. Biointerphases, 18(6), 060801.
https://doi.org/10.1116/6.0003079
Sun, Y., & Davis, E. (2021). Nanoplatforms for targeted stimuli-responsive drug delivery: A review of platform materials and stimuli-responsive release and targeting mechanisms. Nanomaterials, 11(3), 746.
https://doi.org/10.3390/nano11030746
Sweeney, M. L., & Mulholland, M. (2014). Nanoparticles in drug delivery: The role of pharmaceutical excipients. Journal of Drug Delivery Science and Technology, 24(6), 591-596.
https://doi.org/10.1016/j.jddst.2014.06.003
Tomalia, D. A., & Frechet, J. M. J. (2002). Discovery of dendrimers and dendritic polymers: A brief historical perspective. Journal of Polymer Science Part A: Polymer Chemistry, 40(13), 2719-2728.
DOI: 10.1002/pola.10301 Wiley Online Library
Torchilin, V. P. (2011). Tumor delivery of macromolecular drugs based on the EPR effect. Advanced Drug Delivery Reviews, 63(3), 131-135.
https://doi.org/10.1016/j.addr.2010.04.003
Ulbrich, K., & Šubr, V. (2010). Polymeric anticancer drugs with pH-controlled activation. Advanced Drug Delivery Reviews, 62(2), 150-166.
https://doi.org/10.1016/j.addr.2009.11.004
Wang, Y., & Zhao, W. (2014). Targeted drug delivery to cancer by peptides. Peptide Science, 104(3), 221-239.
https://doi.org/10.1002/bip.22421
Zhan, C., & Zhang, X. (2017). Progress in the design of stimuli-responsive polymeric nanoparticles for cancer therapy. Journal of Drug Targeting, 25(9), 755-771.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Magenta Journal De Healthymedi
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
This journal provides direct open access to it's content on the principle that research is freely available to the public supporting a greater global exchange of knowledge. All articles published by Open Access will soon and forever be free for everyone to read and download. The license options defined for this journal are Creative Commons Attribution-ShareAlike (CC BY-SA)
